John Rother President, National Coalition on Health Care Introduction The price of pharmaceuticals has been a top policy issue in the U.S., especially since the introduction of the $1000 per pill Hep C drug Sovaldi in 2017. Drug prices are a top concern for Americans going into the fall elections. The issue is driven by […]
H.R. 1425: The Patient Protection and Affordable Care Enhancement Act
House Democrats unveiled H.R. 1425 which would expand and protect key elements of the Affordable Care Act (ACA). Key provisions of H.R. 1425 include expanding subsidies and eligibility requirements for state-level exchanges. Importantly, states would have the ability to expand premium tax credits beyond 400% of the federal poverty line. H.R. 1425 also fixes the […]
The Hill: Re-Examining the Delivery of High-Value Care through COVID-19
On June 15, NCHC’s John Rother collaborated with Katy Spangler, the Co-Director of Smarter Health Care Coalition, and Dr. A. Mark Fendrick, the Director of the University of Michigan Center for Value-Based Insurance Design, to publish an article in The Hill about high-value care amidst COVID-19. COVID-19 has created unprecedented opportunities for change, including the […]
Insulin: the Life Saving Drug that Needs to be Affordable
Enough is enough–it is time for Congress to address rising insulin prices. Congress has failed to take any action to address the rising cost of insulin. However, the Protecting Access to Biosimilars Act of 2019, introduced by Rep. Diana DeGette (D-CO) in early April, is a promising first step to address the issue. The Energy […]
Reflections on Binding Arbitration Briefing
As Congress and the Trump Administration consider policies to address rising prescription drug prices, the National Coalition on Health Care (NCHC) hosted a Capitol Hill briefing on March 15th to put one promising option on the table: the use of binding arbitration in Medicare Part D to determine prices for a limited set of drugs. […]